Efficacy of a topical sesame/rose geranium oil compound in patients with hereditary hemorrhagic telangiectasia associated epistaxis.

Abstract

Topical Sesame/Rose geranium oil compound is an effective therapy for hereditary hemorrhagic telangiectasia (HHT) associated epistaxis. Cohort Study. Twenty patients with HHT confirmed by the Curaçao criteria were treated with a sesame/rose geranium oil topical compound between January 2010 and June 2011. A treatment evaluation survey was conducted at least 3 months after treatment initiation. Changes in epistaxis severity scores (ESS), patient satisfaction, and any adverse effects were assessed. A total of 20 patients completed the study. The average (SD) age was 54.4 (14.6), and 14 (70%) were female. The median time on rose geranium oil was 183 days (IQR: 114-311). At the conclusion of the study, 18 (90%) were still using rose geranium oil. The majority (75%) of patients subjectively felt improvement with the treatment. The improvement was felt to be gradual in 25% and immediate in 50% of patients. Mean (SD) overall satisfaction using a 10-point Likert scale was 7.8 (3.1), with 50% of the patients reporting a satisfaction rating of 10. Mean (SD) epistaxis severity score (ESS) prior to treatment was 5.3 (1.7). After treatment with sesame/rose geranium oil, mean (SD) ESS was found to be 3.5 (1.8). Treatment with sesame/rose geranium oil was associated with a statistically significant improvement in ESS by 1.81 (P <0.0001). There were no adverse side-effects from the treatment. A sesame/rose geranium oil compound can significantly reduce the epistaxis severity scores of patients with hereditary hemorrhagic telangiectasia-related epistaxis.